Marco Colleoni

Summary

Affiliation: European Institute of Oncology
Country: Italy

Publications

  1. ncbi request reprint Extended adjuvant chemotherapy in endocrine non-responsive disease
    Marco Colleoni
    Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy Electronic address
    Breast 22:S161-4. 2013
  2. ncbi request reprint Neoadjuvant therapy for ER-positive breast cancers
    M Colleoni
    Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Ann Oncol 23:x243-8. 2012
  3. doi request reprint Outcome of special types of luminal breast cancer
    M Colleoni
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 23:1428-36. 2012
  4. ncbi request reprint Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93
    Marco Colleoni
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    J Clin Oncol 24:1332-41. 2006
  5. ncbi request reprint Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects
    M Colleoni
    Division of Medical Oncology, University of Milan School of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 17:232-8. 2006
  6. ncbi request reprint Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93
    Marco Colleoni
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 18:1177-84. 2007
  7. ncbi request reprint Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index
    Marco Colleoni
    European Institute of Oncology, Milan, Italy
    Lancet 366:1108-10. 2005
  8. ncbi request reprint Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor
    M Colleoni
    European Institute of Oncology, Milan, Italy
    Ann Oncol 16:716-25. 2005
  9. ncbi request reprint Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience
    Marco Colleoni
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Clin Oncol 23:1390-400. 2005
  10. ncbi request reprint Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement
    Marco Colleoni
    Division of Medical Oncology, Department of Medicine, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141, Milan, Italy
    J Clin Oncol 23:1379-89. 2005

Detail Information

Publications142 found, 100 shown here

  1. ncbi request reprint Extended adjuvant chemotherapy in endocrine non-responsive disease
    Marco Colleoni
    Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy Electronic address
    Breast 22:S161-4. 2013
    ....
  2. ncbi request reprint Neoadjuvant therapy for ER-positive breast cancers
    M Colleoni
    Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Ann Oncol 23:x243-8. 2012
    ..Tailored neoadjuvant treatments should be considered in patients with ER-positive tumors. Issues focusing on safety, quality of life and patient preference should be routinely discussed...
  3. doi request reprint Outcome of special types of luminal breast cancer
    M Colleoni
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 23:1428-36. 2012
    ..The identification of special types of breast cancer might be of value in assessing prognosis and predicting response to therapy...
  4. ncbi request reprint Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93
    Marco Colleoni
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    J Clin Oncol 24:1332-41. 2006
    ..The value of adjuvant tamoxifen after chemotherapy for premenopausal women with breast cancer has not been adequately assessed...
  5. ncbi request reprint Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects
    M Colleoni
    Division of Medical Oncology, University of Milan School of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 17:232-8. 2006
    ..We previously demonstrated efficacy and impact on serum vascular endothelial growth factor (VEGF) for metronomic cyclophosphamide (C) and methotrexate (M) in patients with breast cancer. New metronomic schedules were investigated...
  6. ncbi request reprint Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93
    Marco Colleoni
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 18:1177-84. 2007
    ..The International Breast Cancer Study Group (IBCSG) conducted two complementary randomized trials to assess whether a treatment-free gap during adjuvant chemotherapy influenced outcome...
  7. ncbi request reprint Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index
    Marco Colleoni
    European Institute of Oncology, Milan, Italy
    Lancet 366:1108-10. 2005
    ..44] for overall survival) [interaction p values=0.0001 for disease-free survival and 0.0019 for overall survival]. Our findings suggest that for women with ER-absent or ER-low tumours, reduction in chemotherapy dose should be avoided...
  8. ncbi request reprint Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor
    M Colleoni
    European Institute of Oncology, Milan, Italy
    Ann Oncol 16:716-25. 2005
    ..Controversy persists about whether chemotherapy benefits all breast cancer patients...
  9. ncbi request reprint Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience
    Marco Colleoni
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Clin Oncol 23:1390-400. 2005
    ..For medial tumors, axillary lymph node staging may not accurately reflect the metastatic potential of the disease...
  10. ncbi request reprint Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement
    Marco Colleoni
    Division of Medical Oncology, Department of Medicine, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141, Milan, Italy
    J Clin Oncol 23:1379-89. 2005
    ....
  11. ncbi request reprint Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies
    M Colleoni
    Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 15:1633-9. 2004
    ..While data exist to clearly correlate small tumor size to better prognosis, the fact that very small breast cancers may express biological markers of dire prognosis leads many to ignore small tumor size during treatment decision-making...
  12. ncbi request reprint Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment
    Marco Colleoni
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Clin Cancer Res 10:6622-8. 2004
    ..The purpose of this research was to identify factors predicting response to preoperative chemotherapy...
  13. ncbi request reprint Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease
    M Colleoni
    Research Unit in Medical Senology, Department of Medicine, Instituto Europeo di Oncologia, Milan, Italy
    Ann Oncol 17:1497-503. 2006
    ..There is limited knowledge about prognosis, and treatment effects in young women with node-negative disease...
  14. pmc Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
    Marco Colleoni
    European Institute of Oncology, Milan, Italy
    J Clin Oncol 29:1117-24. 2011
    ..We investigated whether letrozole monotherapy prolonged overall survival (OS) compared with tamoxifen monotherapy...
  15. ncbi request reprint Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer
    M Colleoni
    Research Unit in Medical Senology at the Department of Medicine, Istituto Europeo di Oncologia, Milan, Italy
    Ann Oncol 18:1632-40. 2007
    ..4%), focal (368, 14.1%), moderate (51, 2.0%) and extensive (170, 6.5%)...
  16. doi request reprint Adjuvant therapies for special types of breast cancer
    Marco Colleoni
    Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Breast 20:S153-7. 2011
    ..Examination of patterns of relapse and treatment response within subpopulations in multiple randomized trials is also mandatory to make progress and reach consensus on how to treat individual patients with special types of breast cancer...
  17. pmc Benefits and adverse effects of endocrine therapy
    M Colleoni
    Research Unit, Medical Senology and International Breast Cancer Study Group, European Institute of Oncology, Milan, Italy
    Ann Oncol 21:vii107-11. 2010
    ..Tailored endocrine treatments should be considered in patients with endocrine-responsive tumors classified as pT1 pN0. Issues focusing on safety, quality of life and subjective side effects should be routinely discussed...
  18. doi request reprint A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer
    Marco Colleoni
    Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Eur J Cancer 46:2216-24. 2010
    ..Tools able to predict pathological complete response (pCR) to preoperative chemotherapy might improve treatment outcome...
  19. pmc Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
    Marco Colleoni
    Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Universita degli Studi di Milano, Milan, Italy
    J Clin Oncol 28:2966-73. 2010
    ....
  20. doi request reprint Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting
    Marco Colleoni
    Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, Milan, Italy
    Breast 18:S137-40. 2009
    ..We review recent developments in the knowledge of established predictive factors in the neo-adjuvant setting...
  21. pmc The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up
    M Colleoni
    Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Ann Oncol 20:1344-51. 2009
    ..The role of adjuvant dose-intensive chemotherapy and its efficacy according to baseline features has not yet been established...
  22. doi request reprint A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer
    M Colleoni
    Department of Medicine, Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 20:1178-84. 2009
    ..We aimed to predict disease-free survival (DFS) in patients who failed to achieve a pathologic complete remission (pCR) after preoperative chemotherapy (PC)...
  23. doi request reprint Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy
    Marco Colleoni
    Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 116:359-69. 2009
    ..4, 95% CI 3.5-11.6, for DFS; HR 3.6 95% CI 2.4-5.6 for OS). Response and outcome after PCT are correlated with the degree of expression of steroid hormone receptors. Studies on tailored preoperative therapies are needed...
  24. ncbi request reprint Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy
    M Colleoni
    Unit of Research in Medical Senology, Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 19:465-72. 2008
    ..To identify the role of estrogen (ER), progesterone (PgR), epidermal growth factor 1 (HER1), and HER2 receptors in predicting response to preoperative chemotherapy...
  25. pmc Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
    M Colleoni
    European Institute of Oncology, Milan, Italy
    Br J Cancer 86:1705-14. 2002
    ....
  26. ncbi request reprint Very young women (<35 years) with operable breast cancer: features of disease at presentation
    M Colleoni
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 13:273-9. 2002
    ..Breast cancer rarely occurs in young women. Our knowledge about disease presentation, prognosis and treatment effects are largely dependent upon older series...
  27. ncbi request reprint Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group
    M Colleoni
    European Institute of Oncology, Milan, Italy
    J Clin Oncol 18:584-90. 2000
    ....
  28. ncbi request reprint Identifying breast cancer patients at high risk for bone metastases
    M Colleoni
    International Breast Cancer Study Group, Division of Medical Oncology, European Institute of Oncology, Milan, Ospedali Civili, Brescia, Italy The International Ludwig Breast Cancer Study Group
    J Clin Oncol 18:3925-35. 2000
    ..To identify patient populations at high risk for bone metastases at any time after diagnosis of operable breast cancer, because these patients are potential beneficiaries of treatment with bisphosphonates...
  29. ncbi request reprint Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors
    M Colleoni
    Division of Medical Oncology, Istituto Europeo di Oncologia, Milan, Italy
    Ann Oncol 11:1057-9. 2000
    ..To test this hypothesis we evaluated the responsiveness to preoperative chemotherapy in patients with ER and progesterone receptors (PgR)-absent tumors...
  30. ncbi request reprint Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer
    M Colleoni
    European Institute of Oncology, Milan, Italy
    J Clin Oncol 19:4141-9. 2001
    ..We investigated tumor- and patient-related features that might influence the response to perioperative chemotherapy (PeCT) compared with no adjuvant therapy for patients with node-negative breast cancer...
  31. ncbi request reprint Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase
    M Colleoni
    Department of Medicine, University of Milan School of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 14:1477-83. 2003
    ....
  32. ncbi request reprint Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels
    M Colleoni
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 13:73-80. 2002
    ..Alternative mechanisms of efficacy have been ascribed to several common anticancer agents, including cyclophosphamide (CTX), methotrexate (MTX), anthracyclines and taxanes, postulating an antiangiogenic activity...
  33. doi request reprint Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy
    Claudia D'Alessandro
    Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Breast J 14:435-41. 2008
    ..91; 95% CI 1.69-20.7; p = 0.005), in particular if HER2/neu overexpression was detected (HR: 16.5; 95% CI 4.24-64.5; p < 0.0001). New multimodality and targeted strategies should be explored in endocrine nonresponsive breast cancer...
  34. doi request reprint Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features
    Alessandra Balduzzi
    Research Unit of Medical Senology, European Institute of Oncology, Milan, Italy
    Anticancer Drugs 20:197-203. 2009
    ..A non-negligible rate of progressive disease was observed, suggesting careful monitoring of the patients. Further studies evaluating the potential benefit of bevacizumab in neoadjuvant treatment need to be tested...
  35. pmc A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer
    Silvia Dellapasqua
    Medical Senology Research Unit and Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Breast 21:621-8. 2012
    ..To develop a Risk Score (RS) to predict distant recurrence among premenopausal women with node-negative endocrine-responsive early breast cancer...
  36. ncbi request reprint A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer
    Andrea Rocca
    Unit of Research in Medical Senology, Department of Medicine, Division of Pathology, University of Milan School of Medicine, Italy
    Anticancer Drugs 17:1201-9. 2006
    ..Perioperative chemotherapy failed to show an increase in the pathological complete remission rate. A biological effect on Ki-67 expression was demonstrated...
  37. ncbi request reprint Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel
    Rosalba Torrisi
    Research Unit of Medical Senology, European Institute of Oncology, Via Ripamonti, 435 20141, Milan, Italy
    Cancer Chemother Pharmacol 62:667-72. 2008
    ..No specific treatment guidelines are available for triple-negative breast cancers, defined by a lack of expression of estrogen (ER), progesterone (PgR), and HER2 receptors...
  38. doi request reprint Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity
    Giuseppe Viale
    Division of Pathology, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 116:317-28. 2009
    ..EGFR immunoreactivity significantly correlates with worse prognosis in patients with triple-negative IDC, supporting further studies on the correlation between the degree of EGFR expression and outcome of triple negative breast cancer...
  39. pmc Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
    Laura Orlando
    Unit of Research in Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    BMC Cancer 6:225. 2006
    ..We therefore tested the activity of the combination of Trastuzumab with metronomic, low dose chemotherapy with cyclophosphamide (CTX) and methotrexate (MTX) in metastatic breast cancer (MBC)...
  40. doi request reprint Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology, European Institute of Oncology, Via Ripamonti 435, Milan, Italy
    Breast 20:34-8. 2011
    ..To explore the activity of pegylated liposomal doxorubicin (PLD) as neoadjuvant therapy of breast cancer...
  41. doi request reprint Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer
    Laura Orlando
    Research Unit Medical Senology, European Institute of Oncology, Milan, Italy
    Breast 17:506-11. 2008
    ..We analyzed the role of Topo II gene status in the prediction of pathological complete remission (pCR) after primary anthracycline-based chemotherapy in non- endocrine responsive breast cancers overexpressing Her2/neu...
  42. doi request reprint Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features
    Emilia Montagna
    Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Breast Cancer Res Treat 124:689-99. 2010
    ..A substantial rate of relapse was observed for patients with large tumors and with clinical nodal involvement at baseline. Further improvement in adjuvant treatment might be warranted...
  43. doi request reprint Positive axillary sentinel lymph node: is axillary dissection always necessary?
    Viviana Galimberti
    Division ofSenology, European Institute of Oncology, Milan, Italy
    Breast 20:S96-8. 2011
    ..Ancillary analyses of the IBCSG 23-01 and AMAROS trials, still in follow-up, may be able to do this...
  44. doi request reprint Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors
    Rosalba Torrisi
    Research Unit in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 17:654-60. 2008
    ..Endocrine therapy administered together with new intravenous, containing regimens should be explored in the preoperative treatment of endocrine responsive breast cancer...
  45. doi request reprint Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer
    Silvia Dellapasqua
    Medical Senology Research Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 20:319-23. 2011
    ..To evaluate the role of pegylated liposomal doxorubicin with low-dose metronomic cyclophosphamide as primary systemic treatment in locally advanced breast cancer...
  46. ncbi request reprint Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution
    Mattia Intra
    Division of Breast Surgery, European Institute of Oncology, Milan, Italy
    Cancer 101:905-12. 2004
    ..Synchronous bilateral invasive breast carcinoma (SBIBC) ranged in incidence from 0.3% to as high as 12%...
  47. ncbi request reprint Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy
    Maria Teresa Sandri
    Unit of Laboratory Medicine, European Institute of Oncology, Milan, Italy
    Cancer 110:509-17. 2007
    ..The aim of the study was to evaluate the prognostic and predictive role of serum HER-2/neu and serum EGFR in breast cancer patients treated with low-dose chemotherapy...
  48. ncbi request reprint Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer
    Andrea Rocca
    Research Unit in Medical Senology, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Anticancer Res 29:5111-9. 2009
    ..The prognostic role of serum levels of molecular biomarkers during the perioperative period in patients with early breast cancer is not clear...
  49. doi request reprint Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab
    Silvia Dellapasqua
    Medical Senology Research Unit, Department of Medicine, European Institute of Oncology, Milan, Italy
    Breast 21:309-13. 2012
    ..There is an urgent need for the identification of commonly assessable predictive factors in the treatment of patients with metastatic breast cancer...
  50. doi request reprint Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?
    Viviana Galimberti
    Division of Senology, Unit of Molecular Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Breast Cancer Res Treat 131:819-25. 2012
    ..Nevertheless, a subset of patients might be at high risk of developing overt axillary disease and efforts should be made to identify such patients by ancillary analyses of the results of ongoing or recently published clinical trials...
  51. doi request reprint Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Via Ripamoniti 435, Milan, Italy
    J Natl Cancer Inst 100:207-12. 2008
    ..Thus, Ki-67 labeling index was an independent prognostic factor but was not predictive of better response to adjuvant chemotherapy in these studies...
  52. ncbi request reprint Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features
    Giuseppe Curigliano
    European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 5:125-30. 2004
    ..The development of more effective therapies for very young women with breast cancer requires tailored treatment investigations and research focused on issues specific to these patients...
  53. doi request reprint Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer
    Silvia Dellapasqua
    Medical Senology Research Unit and Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    J Clin Oncol 26:4899-905. 2008
    ..Metronomic chemotherapy has shown efficacy in patients with metastatic breast cancer. When used in association with targeted antiangiogenic drugs, it was more active than metronomic therapy alone in preclinical and clinical studies...
  54. doi request reprint Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome
    Emilia Montagna
    Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 13:31-9. 2013
    ..This study assesses outcome in terms of disease-free survival (DFS) and overall survival (OS) of special types of triple-negative breast cancer (TNBC)...
  55. doi request reprint Repeating conservative surgery after ipsilateral breast tumor reappearance: criteria for selecting the best candidates
    Oreste Gentilini
    Division of Breast Surgery, European Institute of Oncology, Milan, Italy
    Ann Surg Oncol 19:3771-6. 2012
    ..Mastectomy is still considered the treatment of first choice in patients with ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery (BCS) and whole-breast radiotherapy...
  56. ncbi request reprint Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression
    Andrea Rocca
    Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Cancer Chemother Pharmacol 61:965-71. 2008
    ..The aim of the present study was to ascertain the predictive value of p63 immunoreactivity in patients treated preoperatively with regimens including cisplatin and/or anthracyclines...
  57. doi request reprint Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology, European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 10:483-8. 2010
    ..Given its low cardiotoxicity, the combination of PLD and trastuzumab appears most attractive in the treatment of human epidermal factor receptor 2 (HER2)-positive breast cancer...
  58. doi request reprint Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial
    Viviana Galimberti
    Molecular Senology Unit, Senology Division, European Institute of Oncology, Milan, Italy
    Lancet Oncol 14:297-305. 2013
    ..We designed IBCSG trial 23-01 to determine whether no axillary dissection was non-inferior to axillary dissection in patients with one or more micrometastatic (≤2 mm) sentinel nodes and tumour of maximum 5 cm...
  59. doi request reprint Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity
    Emilia Montagna
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 12:207-14. 2012
    ..The analysis of the results suggests that the metronomic chemotherapy combined with bevacizumab and erlotinib is effective and well tolerated...
  60. doi request reprint Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation
    Emilia Montagna
    Division of Medical Oncology, Department of Medicine, Unit Research of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast Cancer Res Treat 129:867-75. 2011
    ..The outcome of OBC patients is comparable with that of matched patients with small sized breast cancer. High risk of relapse and death was observed in OBC patients with triple negative tumours and extensive nodal involvement...
  61. doi request reprint Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years
    Mattia Intra
    Division of Breast Surgery, European Institute of Oncology, Milan, Italy
    Ann Surg 247:315-9. 2008
    ....
  62. doi request reprint Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology at the Department of Medicine, European Institute of Oncology, Milano, Italy
    Breast Cancer Res Treat 126:431-41. 2011
    ....
  63. doi request reprint Timing of adjuvant systemic therapy and radiotherapy after breast-conserving surgery and mastectomy
    Alessandra Balduzzi
    Research Unit of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Cancer Treat Rev 36:443-50. 2010
    ..This review focuses on the effects of timing of chemotherapy-radiotherapy and risks of relapse, in terms of locoregional and distant recurrence in patients with operable breast cancer...
  64. doi request reprint Preoperative therapy with trastuzumab and oral vinorelbine (+/- endocrine therapy) in patients with HER2-positive breast cancer
    Monica Iorfida
    Unit of Research in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Breast 19:128-32. 2010
    ..Combined trastuzumab and intravenous vinorelbine yielded high clinical activity as preoperative treatment in patients (pts) with HER 2/neu positive breast cancer...
  65. doi request reprint Local therapy for breast cancer in malignant lymphoma survivors
    Mattia Intra
    Division of Breast Surgery, European Institute of Oncology, Milan, Italy
    Breast 20:S99-103. 2011
    ..We performed a retrospective review to assess the potential of performing breast conservative surgery and intraoperative radiotherapy with electrons (ELIOT), in these patients...
  66. ncbi request reprint Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 16:73-80. 2007
    ..Further studies combining chemotherapy and endocrine agents are warranted in patients with hormone receptor-positive tumors...
  67. doi request reprint Breast-conserving surgery in 201 very young patients (<35 years)
    Oreste Gentilini
    Division of Breast Surgery, European Institute of Oncology, Via Ripamonti 435, Milan, Italy
    Breast 19:55-8. 2010
    ..Surgical treatment of breast cancer in very young patients (<35 years) is still a matter of debate, since age is a predictive factor of local recurrence after breast conservation...
  68. doi request reprint Invasive lobular breast cancer: subtypes and outcome
    Monica Iorfida
    Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 133:713-23. 2012
    ..The outcome of ILC significantly correlated with histological and immunohistochemically defined molecular subtypes. New tailored strategies should be explored in these subgroups of patients with poor outcome...
  69. ncbi request reprint Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer
    Laura Orlando
    Unit of Research in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Anticancer Drugs 17:961-7. 2006
    ..Metronomic chemotherapy can induce prolonged clinical benefit in metastatic breast cancer, supporting its role as an additional therapeutic tool in the treatment of patients with metastatic breast carcinoma...
  70. doi request reprint Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer
    Giuseppe Curigliano
    Department of Medicine, Division of Medical Oncology, Istituto Europeo di Oncologia, Milano, Italy
    J Clin Oncol 27:5693-9. 2009
    ..To assess the prognostic role of HER2 overexpression/amplification in patients with node-negative, pT1a-b breast cancers...
  71. doi request reprint Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution series
    Giuseppe Viale
    European Institute of Oncology, University of Milan, Italy
    Breast Cancer Res Treat 117:211-4. 2009
    ..Classical lobular histology is not an independent factor in the prognosis of early breast cancer...
  72. doi request reprint Sentinel lymph node biopsy in multicentric breast cancer: five-year results in a large series from a single institution
    Oreste Gentilini
    Division of Senology, European Institute of Oncology, Milano, Italy
    Ann Surg Oncol 18:2879-84. 2011
    ..This study was designed to present the 5-year results of patients with multicentric breast cancer who underwent sentinel lymph node biopsy (SLNB) in a single institution...
  73. doi request reprint Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy
    Laura Gilardi
    Division of Nuclear Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Eur J Nucl Med Mol Imaging 37:1834-41. 2010
    ....
  74. ncbi request reprint Results of chest wall resection for recurrent or locally advanced breast malignancies
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 16:297-302. 2007
    ....
  75. ncbi request reprint HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17
    Rosalba Torrisi
    Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Eur J Cancer 43:2339-44. 2007
    ..Our results suggest that FISH testing should be considered for tumours with 50% positive stained cells and that polysomy 17 without amplification is not associated with poor prognostic features...
  76. ncbi request reprint Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter
    Giuseppe Curigliano
    Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Support Care Cancer 15:1213-7. 2007
    ..The aim of this study was to evaluate the efficacy and safety of low-dose aspirin for the prevention of VTE...
  77. ncbi request reprint Unnecessary axillary node dissections in the sentinel lymph node era
    Mattia Intra
    Division of Breast Surgery, European Institute of Oncology, Via Ripamonti, 435, 20141 Milan, Italy
    Eur J Cancer 43:2664-8. 2007
    ..As the clinical indications to SNB are progressively extending to encompass most breast cancer patients with non-metastatic disease who were previously excluded, great effort should be made to avoid 'unnecessary ALNDs'...
  78. ncbi request reprint Adjuvant endocrine therapy for premenopausal women with early breast cancer
    Silvia Dellapasqua
    Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Clin Oncol 23:1736-50. 2005
  79. pmc Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy
    Patrizia Mancuso
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Blood 108:452-9. 2006
    ..005). Preclinical models indicated that the source of apoptotic CECs was most likely the tumor vasculature. CEC kinetics and viability are very promising as predictors of clinical response in patients undergoing metronomic chemotherapy...
  80. ncbi request reprint Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma
    Maria Teresa Sandri
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    Anticancer Res 24:1261-6. 2004
    ..Its extracellular domain (HER2 ECD) can be shed into the circulation. The purpose of this study was to evaluate the predictive value of HER2 ECD in patients with advanced breast cancer...
  81. ncbi request reprint Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG)
    A Goldhirsch
    Department of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 9:489-93. 1998
    ..Therefore, adherence to the 'classical' dose and schedule is recommended when CMF is used in adjuvant therapy...
  82. ncbi request reprint Intermittent continuous infusion of fluorouracil and low-dose oral leucovorin in pretreated breast cancer: a pilot study
    M Colleoni
    Division of Medical Oncology, City Hospital, Castelfranco Veneto, Italy
    Tumori 83:665-8. 1997
    ..Other side effects have included diarrhea and thrombocytopenia. CONCLUSIONS: The schedule has demonstrated moderate activity in heavily pretreated breast cancer, with mucositis as the dose-limiting toxicity...
  83. ncbi request reprint Endocrine therapy of breast cancer
    A Goldhirsch
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 13:61-8. 2002
  84. ncbi request reprint Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group
    A Goldhirsch
    Department of Medicine and Radiation Oncology, European Institute of Oncology, Milan, Italy
    J Clin Oncol 16:1358-62. 1998
    ..These drugs have since been extensively used with or without endocrine therapies and/or other cytotoxic agents. Although doses and schedules have varied widely, the combination of these three drugs is generically referred to as CMF...
  85. doi request reprint Letrozole
    Silvia Dellapasqua
    European Institute of Oncology, Medical Senology Research Unit, Division of Medical Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Expert Opin Drug Metab Toxicol 6:251-9. 2010
    ..This review focuses on letrozole, a third generation aromatase inhibitor, encompassing pharmacodynamic and pharmacokinetic aspects as well as its clinical efficacy and safety...
  86. ncbi request reprint Phase II study of oral L-leucovorin, 120-hour fluorouracil infusion and carboplatin in advanced pancreatic cancer
    M Colleoni
    Division of Medical Oncology, City Hospital, Castelfranco Veneto, Italy
    Tumori 82:573-5. 1996
    ..Toxicity consisted of mucositis, diarrhea and neutropenia. CONCLUSIONS: Patients with metastatic pancreatic carcinoma do not benefit from this treatment schedule...
  87. ncbi request reprint Systemic treatments for women with breast cancer: outcome with relation to screening for the disease
    A Goldhirsch
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 14:1212-4. 2003
    ..Research with tailored approaches on alternative imaging for early detection of breast cancer in high-risk women and on treatments offered according to proper criteria of responsiveness to therapies is warranted...
  88. ncbi request reprint Pharmacokinetics of oral doxifluridine in patients with colorectal cancer
    M G Zampino
    Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 85:47-50. 1999
    ..CONCLUSIONS: A large interpatient pharmacokinetic variability was observed without any significant correlation with the clinical parameters studied...
  89. ncbi request reprint Intrathecal chemotherapy in carcinomatous meningitis from breast cancer
    Laura Orlando
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Anticancer Res 22:3057-9. 2002
    ..We therefore evaluated the efficacy of an ITC regimen for patients presenting with carcinomatous meningitis from breast cancer...
  90. ncbi request reprint Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients
    Roberto Gennari
    Department of Surgery, European Institute of Oncology, Milan, Italy
    Cancer 101:1302-10. 2004
    ..The aim of the study was to evaluate the relation between biologic features at first diagnosis of breast carcinoma and treatment choice for postmenopausal women > or = 50 years to optimize treatment in the elderly...
  91. pmc The 6th Milan Breast Cancer Conference, Milan, Italy, 16-18 June 2004
    Roberto Gennari
    European Institute of Oncology, Milano, Italy
    Breast Cancer Res 7:E1. 2005
  92. ncbi request reprint Sentinel lymph node biopsy is feasible even after total mastectomy
    Mattia Intra
    Division of Breast Surgery, European Institute of Oncology, Milan, Italy
    J Surg Oncol 95:175-9. 2007
    ..Previous mastectomy is unanimously considered to represent an absolute technical contraindication to sentinel lymph node biopsy (SLNB)...
  93. doi request reprint Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years
    Aliana Guerrieri-Gonzaga
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
    Oncologist 14:201-12. 2009
    ..We analyzed risk factors and treatment outcome in a large series of women treated at one institution...
  94. ncbi request reprint New criteria for selecting elderly patients for breast cancer adjuvant treatment studies
    Silvia Dellapasqua
    European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Oncologist 12:952-9. 2007
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  95. ncbi request reprint Innovation in care and research: meeting highlights from the seventh Milan Breast Cancer Conference (Milan, 15-17 June, 2005)
    Saverio Cinieri
    European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 15:232-45. 2006
    ..This meeting report summarizes the highlights of the 12 sessions...
  96. ncbi request reprint Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen
    L Orlando
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Anticancer Res 21:4135-9. 2001
    ....
  97. pmc Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity
    R Torrisi
    Department of Medicine, Research Unit of Medical Senology, European Institute of Oncology Milan, Milan, Italy
    Br J Cancer 99:1564-71. 2008
    ..In conclusion, bevacizumab is feasible and active in association with primary chemoendocrine therapy for ER-positive tumours in terms of proliferation inhibition, clinical response and antiangiogenic activity...
  98. ncbi request reprint Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer
    G Ferretti
    Division of Medical Oncology, European Institute of Oncology, Milano, Italy
    Clin Cancer Res 6:2393-400. 2000
    ..8% test accuracy. The method proposed demonstrated to be specific, accurate, and at relatively low cost but limited by low sensitivity in detecting the presence of neoplastic cells in patients with resectable non-small cell lung cancer...
  99. ncbi request reprint Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype
    L Orlando
    Division of Medical Oncology, Department of Medicine, Division of Pathology and Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
    Ann Oncol 16:1094-9. 2005
    ..We retrospectively evaluated the clinical relevance of selected immunohistochemical features of tumors in three cohorts of patients with typical medullary (MC), 'atypical' medullary (AMC) or ductal (DC) breast carcinoma...
  100. ncbi request reprint Intrapericardial treatment of neoplastic pericardial effusions
    A Martinoni
    Cardiology Unit, European Institute of Oncology IRCCS, University of Milan, Milan, Italy
    Herz 25:787-93. 2000
    ..Real randomized, case-control studies are moreover required to assess the gold standard of malignant pericardial effusions treatment...
  101. doi request reprint Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure
    E Montagna
    Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Breast Cancer Res Treat 118:385-94. 2009
    ..Treatment recommendations for systemic therapy should not take into account the presence of a single micrometastatic lymph node identified during complete serial sectioning of sentinel node(s)...